Overview

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, multicenter, extension study. Subjects with non-Hodgkin's lymphoma (NHL) (excluding chronic lymphocytic lymphoma [CLL], small lymphocytic lymphoma [SLL], and mantle cell lymphoma [MCL]) who completed a prior ABT-199 study, or were active and assigned to ABT-199 when the study was completed, may roll over into this extension study. Subjects will receive ABT-199 during this study.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Collaborator:
Genentech, Inc.
Treatments:
Venetoclax